Our Impact
For more than 100 years, our people have been passionate about helping others. Otsuka’s approach to Social Impact is grounded in the idea of creating better health worldwide by tackling the issues that only Otsuka can solve.
We envision a world where everyone can access the healthcare they need. A place where every person living with a mental illness or chronic disease feels supported and empowered to live life on their terms. It is our privilege to walk alongside our communities as allies and advocates to overcome barriers and reduce inequities.
Our promise is to invest in products, programs, policies, and advocacy efforts that help remove stigma and discrimination, increase access to care, and address social determinants of health. This is not just our promise, it is our passion.
Our Focus
We are committed to making a positive impact through our Social Impact
work in the areas of:
STIGMA AND DISCRIMINATION
We support nonprofit organizations and solutions that address and reduce stigma and discrimination toward those with mental illness, brain diseases, or other chronic diseases.
ACCESS TO CARE
We support increasing access to treatment for those living with a mental illness, brain diseases, or other chronic diseases.
SOCIAL DETERMINANTS OF HEALTH
We are committed to addressing economic and social factors that impact the health status and quality of life for people and communities.
STIGMA AND DISCRIMINATION
We support nonprofit organizations and solutions that address and reduce stigma and discrimination toward those with mental illness, brain diseases, or other chronic diseases.
ACCESS TO CARE
We support increasing access to treatment for those living with a mental illness, brain diseases, or other chronic diseases.
SOCIAL DETERMINANTS OF HEALTH
We are committed to addressing economic and social factors that impact the health status and quality of life for people and communities.
SPONSORSHIPS
We support nonprofits in a variety of ways, including through sponsorship opportunities that propel and amplify their work. We are proud to provide funding to organizations such as the National Alliance on Mental Illness (NAMI), the National Kidney Foundation, the Depression and Bipolar Support Alliance, and many more.
CHARITABLE GRANTS & DONATIONS
We collaborate with leading nonprofits that share our commitment to ensure that everyone can access the healthcare they need. Together with these organizations, we are working to empower people living with mental illness, brain diseases, and other chronic diseases. By providing Otsuka resources to these nonprofits, we support and advance this work in local and global communities.
SOZOSEI FOUNDATION
The Sozosei Foundation is an independent nonprofit philanthropic entity that was founded in 2019. The Foundation’s primary focus is to increase access to mental healthcare to eliminate the inappropriate use of jails and prisons for the diagnosis and treatment of mental illness in the United States. The Foundation works toward this goal by making grants to 501(c)(3) organizations across the US and by hosting convenings, including the Sozosei Summit to Decriminalize Mental Illness. Otsuka America Pharmaceutical, Inc does not control or influence the Sozosei Foundation.
OTSUKA PATIENT ASSISTANCE FOUNDATION, INC.
The Otsuka Patient Assistance Foundation, Inc (OPAF) is an independent nonprofit foundation dedicated to patient health and wellness. In addition to assistance with free Otsuka medication, OPAF also assists eligible patients with additional barriers that may affect their health.
OPAF recognizes that patients face unique challenges that negatively impact their health journey. OPAF is dedicated to being a foundation of excellence that focuses on providing free health and wellness solutions through the OPAF Resource and Solutions Center. OPAF provides assistance with finding external, alternative resources to assist patients with nutrition, housing and other financial issues, medical financial issues, disease education, and transportation concerns related to receiving care.
Otsuka America Pharmaceutical, Inc does not control or influence how Otsuka Patient Assistance Foundation, Inc distributes funds.
*Sozosei Foundation and OPAF are separate 501(c)3 entities, subject to their respective Bylaws and the approval of their respective Board of Directors
MAKING A MEANINGFUL DIFFERENCE
As a purpose-driven organization, we believe in empowering all Otsuka-people to make a meaningful difference in the communities where they live and work. We call this work Otsuka Cares. Through our Otsuka Cares program, we engage our employees in volunteering and giving year-round. Learn more about the ways we enable Otsuka-people to make an impact below.
MATCHING DONATIONS
Otsuka doubles employee donations by matching them dollar for dollar, up to $2,500 annually.
DOLLAR FOR DOERS
For every one hour an Otsuka-person volunteers, Otsuka provides $10 to donate to the nonprofit of their choosing.
VOLUNTEER TIME OFF
All Otsuka-people receive 16 hours of paid time off to volunteer each year.
INDEPENDENT MEDICAL EDUCATION FOR HEALTHCARE PROFESSIONALS (IME)
We are committed to funding innovative education and independent studies that support healthcare professionals in their learning and development.
Visit the Otsuka Grants Website to learn more about areas of interest, apply, or get answers to frequently asked questions.
To be eligible for consideration, the program must:
- Advance the systems-based practice of medicine
- Improve the accessibility, quality, and delivery of patient care
- Deliver education solutions that reinforce learning and change in HCPs through the rigorous application of adult learning principles and scientific evidence
You can also contact us at 800-438-6120 or send an email to grants@otsuka-us.com
INVESTIGATOR-SPONSORED STUDIES (ISS)
In our dedication to serving unmet medical needs, we support independent investigator-sponsored studies that have the potential to impact the disease of interest. Otsuka may provide financial support and/or study drugs, but is not the study sponsor and assumes no sponsor obligations.
Shared Commitment
Our commitment to making a positive impact for others is a common thread across additional, related efforts that Otsuka and Otsuka-people are privileged to champion.
DIVERSITY, EQUITY, AND INCLUSION
Otsuka-people believe that our current and future success is grounded in science and innovations that are fueled by diversity of lived experiences and thoughts. We are creating an inclusive, equitable today and tomorrow for our people, patients, and communities.
GLOBAL GOOD
With Otsuka offices all around the world, our reach extends outward to create global good. Guided by the corporate philosophy, the Otsuka group works to solve social issues through its businesses and contribute to the creation of a healthy and sustainable society.
The advancement of healthier lives begins with our own fair, open, and honest community. Our comprehensive compliance program reflects our commitment to conducting business honestly, ethically, and in compliance with the laws and regulations where we operate. Otsuka innovates with integrity, never losing sight of the trust that others have placed in us. Compliance is the responsibility of every colleague, and managers play a crucial role in setting the example for compliant behavior and practices.
At Otsuka, we treat one another with dignity and respect. As a caring corporate citizen, we take responsibility for our actions in the local, national, and international communities where we operate.
See the full details about our Code of Ethics and Professional Conduct for employees here, and for suppliers here.
Vermont Pharmaceutical Marketer Price Disclosure
In accordance with Vermont law 18 V.S.A. § 4633, marketers of certain pharmaceutical products are required to disclose to Vermont doctors and other prescribers average wholesale price (AWP) information for drugs they market as well as the AWPs of other drugs in the same therapeutic class.
Listings within these charts do not imply that products are interchangeable or have the same efficacy or safety.
Please refer to each product’s FDA-approved prescribing information for such determinations.
The AWP information identified on the disclosure forms is based on third-party published data and may not be reflective of prices actually charged to or paid for by any customer.
OUR CODE, POLICIES, AND PROCEDURES
The US Code of Ethics and Professional Conduct (the “Code”) describes Otsuka’s fundamental values and summarizes the policies and legal requirements that apply to our business. The Code is supported by policies and procedures governing our general business activities as well as those activities related to marketing and sales of our pharmaceutical products and interactions with healthcare professionals.
EFFECTIVE TRAINING, COMMUNICATION, AND CONTINUING ADVICE
Otsuka provides Compliance and Ethics learning programs for all employees and relevant third-party suppliers. General compliance training includes understanding our Compliance Program, the Code, policies and standard operating procedures. Otsuka provides training specific to federal healthcare program and Food & Drug Administration (“FDA”) requirements related to promotional and product-related functions, training to prevent fraud and corruption, as well as training regarding Good Manufacturing and Good Clinical Practices. The Ethics & Compliance Group also works with its business partners throughout the Company to provide continuing advice on compliance and quality matters. Finally, we ensure that our education and training programs are effective by applying adult learning principles.
OPEN LINES OF COMMUNICATION
Otsuka has a Speak-Up policy, which requires all employees to speak up when they have a question regarding a Company policy or procedure, or when they are faced with an ethical dilemma. All employees should feel comfortable requesting guidance from the Company, and are encouraged to discuss any questions, concerns, complaints or suggestions with their supervisor, Human Resources, Ethics & Compliance (“E&C”), or Legal Affairs.
CONFIDENTIAL REPORTING AND INTERNAL INVESTIGATIONS; PROMPT RESPONSE TO PROBLEMS AND CORRECTIVE ACTIONS
Our Code requires employees to report any known or suspected violations of company policies to their supervisor or to the Chief Compliance Officer (“CCO”). Additionally, Otsuka’s policies strictly prohibit any adverse action against any person who, in good faith, reports known or suspected compliance issues. The Company has an established toll-free telephone number, 1-800-363-5670, for reporting violations or possible violations of the Compliance Program or other company policies. In the event the Company becomes aware of any suspected noncompliance with the Compliance Program or the relevant policies and procedures, through either routine monitoring or a reported violation, the Chief Compliance Officer will investigate the circumstances surrounding the suspected noncompliance to determine whether a violation has occurred. If the investigation reveals a violation, the Company will take appropriate corrective action, which may involve disciplinary actions up to and including termination.
INCENTIVES, PUBLICIZED DISCIPLINARY GUIDELINES, AND DISCIPLINARY MEASURES
All Otsuka colleagues are constantly evaluated on their adherence to the principles expressed in our Code. The potential disciplinary actions that can be taken when employees are found to have violated Company policies, or have failed to report violations, of which they were aware, are explained in the Code. Our Code also highlights the heightened responsibilities of supervisors with regard to compliance.
OVERSIGHT, AUTONOMY AND RESOURCES; COMPLIANCE OFFICER AND COMMITTEES
The CCO is charged with monitoring the Compliance Program, and serves as the primary contact for issues relating to compliance with the Program. The CCO reports directly to the Chief Executive Officer (“CEO”), and provides periodic reports to the Board of Directors and the Audit Committee of the Board of Directors. The CCO also serves as the Chair of the Compliance Committee, which is composed of senior management personnel and provides oversight and guidance for compliance activities.
CONTINUOUS IMPROVEMENT, PERIODIC TESTING AND REVIEW THROUGH INTERNAL AUDITING AND MONITORING
Otsuka’s Compliance Program is continuously evolving, incorporating learning from internal auditing and monitoring, as well as external trends and developments. Each year, a compliance auditing and monitoring plan is developed to test the implementation and effectiveness of compliance policies and procedures, utilizing both risk-based and random sampling techniques. Results of each audit and activity monitoring are shared with the appropriate Business Owners and the Compliance Committee to assess any needed follow-up actions.
RISK ASSESSMENT
Otsuka’s Compliance Program utilizes a risk-based approach to focus resources. We routinely assess the risks inherent with new programs and concepts, and we consider the level of risk when designing audit and monitoring plans. Additionally, Otsuka regularly seeks a third-party view of its operations, commissioning risk assessments from external parties.
THIRD PARTY DUE DILIGENCE AND PAYMENTS
All third parties with whom Otsuka does business are subject to screening to ensure that they do not present additional risk to the Company’s business or reputation. Otsuka’s contracts with third parties include compliance training requirements and assurances, audit rights, and other provisions depending on the type of service provided by the third party.
MERGERS AND ACQUISITIONS: PRE-ACQUISITION DUE DILIGENCE AND POST-ACQUISITION INTEGRATION
Otsuka conducts due diligence on all potential acquisition targets, as well as on all companies with whom it enters into joint promotion and development agreements. This due diligence includes, but is not limited to, an assessment of the compliance program, policies and procedures, and internal controls. After acquisition, Otsuka will ensure a thorough integration, ensuring that new colleagues understand its commitment to compliance and our Compliance Program, and that internal controls extend to the acquisition target.